{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:59Z","timestamp":1793090339334,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105625","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:21:48Z","timestamp":1790608908000},"page":"105625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From translation milestones to clinical breakthroughs: Decision-making hubs and translational strategies for RNA-binding proteins in the immunotherapy of haematological malignancies"],"prefix":"10.1016","volume":"227","author":[{"given":"Peng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4523-6749","authenticated-orcid":false,"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105625_bib1","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.gmg.2024.100032","article-title":"RNA binding proteins (RBPs) on genetic stability and diseases","volume":"12","author":"Aborode","year":"2025","journal-title":"Glob. Med. Genet."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105625_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179552","article-title":"The Role of RNA-Binding Proteins in Hematological Malignancies","volume":"23","author":"Aguilar-Garrido","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105625_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-024-02392-8","article-title":"Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy","volume":"41","author":"Al-Hawary","year":"2024","journal-title":"Med. Oncol. (North. Lond. Engl. )"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105625_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrm.2017.7","article-title":"Biomolecular condensates: organizers of cellular biochemistry","volume":"18","author":"Banani","year":"2017","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"7683","key":"10.1016\/j.critrevonc.2026.105625_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature24678","article-title":"Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control","volume":"552","author":"Barbieri","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105625_bib8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/ITT.S534784","article-title":"T Cells Dysfunction in Multiple Myeloma","volume":"14","author":"Cai","year":"2025","journal-title":"ImmunoTargets Ther."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105625_bib9","article-title":"RNA\u2212binding protein FXR1 stabilizes receptor tyrosine kinase FGFR1 and enhances PI3K\u2212Akt signaling to promote T\u2212cell leukemogenesis","volume":"146","author":"Chen","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cell.2024.11.007","article-title":"YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies","volume":"188","author":"Chen","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib11","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1038\/s41467-022-31818-y","article-title":"High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance","volume":"13","author":"Cort\u00e9s-L\u00f3pez","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105625_bib12","article-title":"CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through CSDE1-eIF3a regulatory complex","volume":"81","author":"Cui","year":"2025","journal-title":"Drug. Resist. Update. Rev. Comment. Antimicrob. Anticancer. Chemother."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105625_bib13","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2023011242","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105625_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1224516","article-title":"IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment","volume":"14","author":"Elcheva","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41375-020-01066-4","article-title":"Targeting RNA-binding proteins in acute and chronic leukemia","volume":"35","author":"Elcheva","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105625_bib16","first-page":"2346","article-title":"Basics of cancer immunotherapy]","volume":"57","author":"Fujioka","year":"2016","journal-title":"Rinsho Ketsueki"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105625_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm1488","article-title":"Molecular mechanisms of translational control","volume":"5","author":"Gebauer","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41587-025-02648-2","article-title":"Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein","volume":"44","author":"George","year":"2026","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib19","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/anie.202012330","article-title":"RNA-PROTACs: Degraders of RNA-Binding Proteins","volume":"60","author":"Ghidini","year":"2021","journal-title":"Angew. Chem. (Int. Ed. Engl. )"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105625_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110778","article-title":"YTHDF2 suppresses the plasmablast genetic program and promotes germinal center formation","volume":"39","author":"Grenov","year":"2022","journal-title":"Cell. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12964-019-0496-2","article-title":"The role of CSDE1 in translational reprogramming and human diseases","volume":"18","author":"Guo","year":"2020","journal-title":"Cell communication signaling CCS"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10238-023-01272-1","article-title":"SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection","volume":"24","author":"Guo","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105625_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1455464","article-title":"Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed\/refractory multiple myeloma","volume":"14","author":"Hamadeh","year":"2024","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105625_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70934","article-title":"Recent Findings in N6-Methyladenosine Modification and Significance in Pancreatic Cancer","volume":"14","author":"Hara","year":"2025","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105625_bib25","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1159\/000495719","article-title":"IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia","volume":"51","author":"He","year":"2018","journal-title":"Cellular Physiology Biochem Inter. J. Experimental Cellular Physiology Biochem. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105625_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrm.2017.130","article-title":"A brave new world of RNA-binding proteins","volume":"19","author":"Hentze","year":"2018","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105625_bib27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood-2018-10-839985","article-title":"RNA-binding proteins in hematopoiesis and hematological malignancy","volume":"133","author":"Hodson","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105625_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189602","article-title":"Dysregulated selective translation in cancer: The pivotal functions of RNA-binding proteins and emerging therapeutic avenues","volume":"1881","author":"Hu","year":"2026","journal-title":"Biochim. Et. Biophys. Acta Rev. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105625_bib29","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-17-2483","article-title":"The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression","volume":"24","author":"Huang","year":"2018","journal-title":"Clinical Cancer Res. Official J. Am. Associ. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105625_bib30","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032813","article-title":"Stress Granules and Processing Bodies in Translational Control","volume":"11","author":"Ivanov","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.hoc.2023.07.003","article-title":"Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy","volume":"37","author":"Johnson","year":"2023","journal-title":"Hematol. \/Oncol. Clin. North. Am."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105625_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.116","article-title":"RNA binding protein-directed control of leukemic stem cell evolution and function","volume":"8","author":"Joshi","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2026.105625_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101144","article-title":"m6A eraser ALKBH5\/treRNA1\/DDX46 axis regulates BCR expression","volume":"62","author":"Kapadia","year":"2025","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10.1016\/j.critrevonc.2026.105625_bib34","article-title":"A Phosphorylation Switch Modulates Configurational Codes in the Oncofetal IGF2BP RNA Binding Paralogs","author":"Kaushik","year":"2026","journal-title":"bioRxiv Prepr. Serv. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41419-023-06413-8","article-title":"The multifaceted role of Fragile X-Related Protein 1 (FXR1) in cellular processes: an updated review on cancer and clinical applications","volume":"15","author":"Khan","year":"2024","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105625_bib36","article-title":"Oncofetal RNA-binding proteins of IGF2BP family suppress IRF-3 and NF-kB dependent transcription downstream of cytosolic RNA sensors","author":"Knox","year":"2026","journal-title":"bioRxiv Prepr. Serv. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105625_bib37","article-title":"A platform for analyzing translational control by RBPs at single-mRNA resolution in cells","volume":"22","author":"Kobayashi","year":"2025","journal-title":"Biophys. Phys."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060690","article-title":"Immunotherapeutic potential of m6A-Modifiers and MicroRNAs in controlling acute myeloid leukaemia","volume":"9","author":"Kumar","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib39","first-page":"355","article-title":"Prognostic Value of IGF2BP3 Gene Expression Levels in Patients with Acute Myeloid Leukemia]","volume":"32","author":"Le","year":"2024","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"10.1016\/j.critrevonc.2026.105625_bib40","article-title":"Dual oncogenic role of RNF220 in AML: linking metabolic rewiring to cell proliferation and immune evasion","volume":"15","author":"Li","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105625_bib41","article-title":"Decoding m(6)A readers: roles of YTHDF proteins in leukemogenesis and cancer immunity","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105625_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.108119","article-title":"IGF2BP3 promotes acute myeloid leukemia cell progression by regulating Semaphorin 4D stability in an m6A-dependent manner","volume":"159","author":"Li","year":"2025","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2026.105625_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.freeradbiomed.2025.07.004","article-title":"FTO inhibition represses B-cell acute lymphoblastic leukemia progression by inducing nucleolar stress and mitochondrial dysfunction","volume":"238","author":"Li","year":"2025","journal-title":"Free. Radic. Biol. & Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105625_bib44","doi-asserted-by":"crossref","DOI":"10.1242\/dev.201890","article-title":"The RNA-binding protein CSDE1 promotes hematopoietic stem and progenitor cell generation via translational control of Wnt signaling","volume":"150","author":"Li","year":"2023","journal-title":"Development (Cambridge England)"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105625_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251968","article-title":"eIF3e-mediated translational checkpoint maintains immune tolerance and prevents lymphoid malignancy","volume":"223","author":"Lin","year":"2026","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105625_bib46","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/s41590-025-02232-5","article-title":"LARP4-mediated hypertranslation drives T cell dysfunction in tumors","volume":"26","author":"Liu","year":"2025","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib47","first-page":"41","article-title":"IGF2BP3 Promoted the Overproliferation of AML Cells via Stability of NRXN2 mRNA","volume":"43","author":"Ma","year":"2026","journal-title":"Turk. J. Haematol. Off. J. Turk. Soc. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41594-018-0178-6","article-title":"Publisher Correction: Structural and molecular mechanisms for the control of eukaryotic 5\u2032-3\u2032 mRNA decay","volume":"26","author":"Mugridge","year":"2019","journal-title":"Nat. Struct. & Mol. Biol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105625_bib49","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/1873-3468.70132","article-title":"Regulation of mRNA metabolism in immune cells","volume":"599","author":"Negi","year":"2025","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1248\/bpb.b22-00478","article-title":"Neuronal RNA-Binding Protein HuD Interacts with Translation Initiation Factor eIF3","volume":"46","author":"Nishisaka","year":"2023","journal-title":"Biol. & Pharm. Bull."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000547531","article-title":"Beyond CAR-T: The Rise of CAR-NK\/T Cells for Haematological Cancer","volume":"149","author":"Noorafrooz","year":"2026","journal-title":"Acta Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105625_bib52","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15252\/embr.201642195","article-title":"The integrated stress response","volume":"17","author":"Pakos-Zebrucka","year":"2016","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105625_bib53","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI80046","article-title":"RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation","volume":"126","author":"Palanichamy","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105625_bib54","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.trecan.2017.05.003","article-title":"RNA-Binding Proteins in Cancer: Old Players and New Actors","volume":"3","author":"Pereira","year":"2017","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10238-025-01902-w","article-title":"Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers","volume":"25","author":"Pirouzbakht","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105625_bib56","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/10428194.2021.2008381","article-title":"RNA-binding proteins as drivers of AML and novel therapeutic targets","volume":"63","author":"Qin","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105625_bib57","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood.2025030336","article-title":"Targeting the METTL1\/m7G axis as a therapeutic strategy in myeloid leukemia","volume":"147","author":"Ren","year":"2026","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-020-0264-6","article-title":"RNA contributions to the form and function of biomolecular condensates","volume":"22","author":"Roden","year":"2021","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.tig.2017.04.003","article-title":"m(6)A in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression","volume":"33","author":"Roignant","year":"2017","journal-title":"Trends genetics TIG"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105625_bib60","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105625_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103409","article-title":"RNA-Binding Proteins in Acute Leukemias","volume":"21","author":"Schuschel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105625_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235508","article-title":"The MYC-Regulated RNA-Binding Proteins hnRNPC and LARP1 Are Drivers of Multiple Myeloma Cell Growth and Disease Progression and Negatively Predict Patient Survival","volume":"15","author":"Seibert","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","article-title":"The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hbpd.2025.05.001","article-title":"YBX1 is required for maintaining PD-L1 expression in intrahepatic cholangiocarcinoma by regulating STAT1 stability in an m5C-dependent manner","volume":"24","author":"Sun","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int. HBPD INT"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105625_bib65","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s43018-025-00977-4","article-title":"TRMT6-mediated tRNA m(1)A modification acts as a translational checkpoint of histone synthesis and facilitates colorectal cancer progression","volume":"6","author":"Tao","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105625_bib66","article-title":"Regulation of Gene Expression Associated With the N6-Methyladenosine (m6A) Enzyme System and Its Significance in Cancer","volume":"10","author":"Tian","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-022-00343-5","article-title":"RNA binding proteins in MLL-rearranged leukemia","volume":"11","author":"Tran","year":"2022","journal-title":"Exp. Hematol. & Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105625_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/biology12071004","article-title":"N(6)-Methyladenosine Directly Regulates CD40L Expression in CD4(+) T Lymphocytes","volume":"12","author":"van Vroonhoven","year":"2023","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030496","article-title":"Nivolumab Plus 5-Azacitidine in Pediatric Relapsed\/Refractory Acute Myeloid Leukemia (AML): Phase I\/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105625_bib70","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.4416","article-title":"The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells","volume":"23","author":"Vu","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib71","article-title":"The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance","volume":"8","author":"Walid","year":"2026","journal-title":"Blood Sci. (Baltimore Md.)"},{"key":"10.1016\/j.critrevonc.2026.105625_bib72","article-title":"CSDE1 in tumour immunology: spatiotemporal translational reprogramming and immune microenvironment remodeling","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105625_bib74","first-page":"1123","article-title":"Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3","volume":"73","author":"Wang","year":"2024","journal-title":"Inflamm. Res. Off. J. Eur. Histamine Res. Soc. [et. al.]"},{"key":"10.1016\/j.critrevonc.2026.105625_bib75","article-title":"Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib76","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1038\/s41467-024-53561-2","article-title":"A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s43556-024-00234-7","article-title":"Single-cell transcriptome profiling of m(6)A regulator-mediated methylation modification patterns in elderly acute myeloid leukemia patients","volume":"5","author":"Wang","year":"2024","journal-title":"Mol. Biomed."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105625_bib78","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","article-title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia","volume":"23","author":"Witkowski","year":"2022","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105625_bib79","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41570-020-0201-4","article-title":"Inhibition of RNA-binding proteins with small molecules","volume":"4","author":"Wu","year":"2020","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.critrevonc.2026.105625_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122527","article-title":"Comprehensive pan-cancer analysis identifies the RNA-binding protein LRPPRC as a novel prognostic and immune biomarker","volume":"343","author":"Wu","year":"2024","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105625_bib81","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bbagrm.2014.10.001","article-title":"RNA-binding proteins, multifaceted translational regulators in cancer","volume":"1849","author":"Wurth","year":"2015","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2025.04.003","article-title":"YTHDF2: a key RNA reader and antitumor target","volume":"46","author":"Xiao","year":"2025","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105625_bib83","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/cam4.3859","article-title":"Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma","volume":"10","author":"Xie","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105625_bib84","article-title":"Exosomal lncRNAs as diagnostic and therapeutic targets in multiple myeloma","volume":"14","author":"Yan","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.56875\/2589-0646.1030","article-title":"Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies","volume":"15","author":"Yang","year":"2022","journal-title":"Hematol. Oncol. Stem Cell. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105625_bib86","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14737159.2017.1381560","article-title":"Discovery and application of immune biomarkers for hematological malignancies","volume":"17","author":"Zafeiris","year":"2017","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib87","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"7671","key":"10.1016\/j.critrevonc.2026.105625_bib88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature23883","article-title":"m(6)A modulates haematopoietic stem and progenitor cell specification","volume":"549","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105625_bib89","article-title":"RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer","volume":"17","author":"Zhang","year":"2026","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s12276-022-00735-x","article-title":"The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability","volume":"54","author":"Zhang","year":"2022","journal-title":"Exp. & Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105625_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1637372","article-title":"METTL1 in human cancers: recognition of their functions, mechanisms and therapeutic value","volume":"19","author":"Zhang","year":"2025","journal-title":"Oncol. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105625_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-024-00477-8","article-title":"METTL1 mediated tRNA m(7)G modification promotes leukaemogenesis of AML via tRNA regulated translational control","volume":"13","author":"Zhao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105625_bib93","first-page":"148","article-title":"Current status and hurdles for CAR-T cell immune therapy","volume":"1","author":"Zhao","year":"2019","journal-title":"Blood science (Baltimore Md. )"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105625_bib94","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tcb.2025.02.003","article-title":"Targeting YTHDF2 impacts the epitranscriptome and overcomes tumor therapy resistance","volume":"35","author":"Zhao","year":"2025","journal-title":"Trends Cell. Biol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105625_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107819","article-title":"Control of Early B Cell Development by the RNA N(6)-Methyladenosine Methylation","volume":"31","author":"Zheng","year":"2020","journal-title":"Cell. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105625_bib96","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41551-025-01514-5","article-title":"Inhibition of LARP4-mediated quiescence exit of naive CD4(+) T cells ameliorates autoimmune and allergic diseases","volume":"10","author":"Zhou","year":"2026","journal-title":"Nat. Biomed. Eng."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105625_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg0470","article-title":"m(6)A demethylase ALKBH5 controls CD4(+) T cell pathogenicity and promotes autoimmunity","volume":"7","author":"Zhou","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105625_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.794754","article-title":"RNA m(6)A Modification in Immunocytes and DNA Repair: The Biological Functions and Prospects in Clinical Application","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105625_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107451","article-title":"Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5","volume":"141","author":"Zhu","year":"2024","journal-title":"Leuk. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:02:44Z","timestamp":1793088164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":99,"alternative-id":["S1040842826005123"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105625","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From translation milestones to clinical breakthroughs: Decision-making hubs and translational strategies for RNA-binding proteins in the immunotherapy of haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105625"}}